Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Current anti-diabetic treatment fails to stop the progressive course of the disease. Recent
studies have revealed a surprisingly high variability in the diabetic phenotype. The
investigators propose that anti-diabetic treatment should ideally target the underlying
pathophysiology of each individual patient. The investigators will therefore test whether the
effect of two approved anti-diabetic drugs differs between individuals at different ends of
the pathophysiological spectrum: 1) patients with poor insulin secretion, here termed SIDD
and 2) patients with high insulin resistance, here termed SIRD. The study may open up a new
avenue for more precise treatment of diabetic patients that would be of immediate clinical
relevance.